JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 153 filers reported holding JUNO THERAPEUTICS INC in Q2 2015. The put-call ratio across all filers is 2.17 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $744,000 | +318.0% | 16,285 | +102.3% | 0.03% | +300.0% |
| Q1 2017 | $178,000 | -34.8% | 8,048 | -44.5% | 0.01% | -50.0% |
| Q4 2016 | $273,000 | -44.8% | 14,494 | -12.3% | 0.02% | -52.9% |
| Q3 2016 | $495,000 | -58.2% | 16,520 | -46.4% | 0.03% | -57.0% |
| Q2 2016 | $1,185,000 | +105.7% | 30,831 | +103.8% | 0.08% | +71.7% |
| Q1 2016 | $576,000 | -6.8% | 15,125 | +30.4% | 0.05% | -11.5% |
| Q2 2015 | $618,000 | – | 11,597 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Biomark Capital Management Co. LLC | 2,168,601 | $65,080,000 | 86.12% |
| Crestline Management, LP | 17,348,799 | $520,637,000 | 66.02% |
| Omega Fund Management, LLC | 1,229,512 | $36,898,000 | 28.17% |
| SIB LLC | 100,000 | $3,001,000 | 2.42% |
| Clarius Group, LLC | 117,896 | $3,538,000 | 1.65% |
| BB BIOTECH AG | 1,405,000 | $42,164,000 | 1.48% |
| Duquesne Family Office | 493,000 | $14,795,000 | 1.31% |
| First Washington CORP | 65,320 | $1,960,000 | 1.10% |
| PFM Health Sciences, LP | 1,124,285 | $33,740,000 | 0.99% |
| Partner Investment Management, L.P. | 18,376 | $551,000 | 0.82% |